European Union: CJEU Decides On Calculation Of SPC Term

Last Updated: 16 October 2015
Article by Christian Fulda and Tetiana Kharkovets

The European Court of Justice ("CJEU") has decided on a matter of great importance for applicants of pharmaceutical patents who have already obtained a supplementary protection certificate ("SPC") on the basis of a marketing authorization ("MA") or who intend to do so. The question answered by the decision in C-471/14 Seattle Genetics Inc. related to the calculation of the SPC term, and it has a direct impact on the duration of the SPC protection.

SPCs provide additional protection for pharmaceutical patents after their expiry and are intended to compensate for the long and costly authorization procedure necessary to bring a product to market. The duration of an SPC is calculated according to Art. 13 of the SPC Regulation as an interval between the patent filing and "the date of the first authorization to place the product on the market in the Community" reduced by five years. The maximum duration allowed is limited to five years. Whereas the filing date of the basic patent is unambiguous, it is unclear whether the date of the decision or the notification date should be considered. In fact, the latter results in a longer protection. Given that up to 80 percent of the revenue derived from a pharmaceutical product is achieved during the supplementary protection time, even one additional day is of great importance. Currently, different jurisdictions use different criteria. As a consequence, the duration of an SPC for the same product can deviate by several days in different European countries.

An SPC is a national right granted by the national patent offices. In Europe, however, this right is governed by EU legislation, namely by EU Regulation No. 469/2009 (the "SPC Regulation"). As a consequence, national courts refer to the CJEU if there are uncertainties in the interpretation of the law.

In the present case, Seattle Genetics appealed the decision of the Austrian Patent Office, which uses the issuance date of the MA for the SPC term calculation. The Higher Regional Court of Vienna (Oberlandesgericht Wien) referred two questions to the CJEU: (i) whether the date of the MA should be interpreted according to the national or to the European Community law, and (ii) in the latter case, whether the date is the date of the issuance of the decision or the date of notification to the MA applicant. Due to the importance of these questions, the Greek, Italian, Lithuanian, and Latvian governments, as well as the European Commission, submitted their written statements.

Prior to the final decision, the CJEU Advocate-General, Niilo Jääskinen, issued his Opinion at the request of the CJEU. The final decision essentially confirmed his point of view.

With respect to the first question, all statements except for that of the Italian government favored the position that Community law is to be applied. The Advocate-General and the CJEU came to the same conclusion after a thorough consideration of nature and purpose of the Regulation and the previous case law. In particular, the Advocate-General pointed out that regulations of the Community law, like Art. 13 of the SPC Regulation, should be interpreted uniformly if not otherwise determined in the Regulation itself. Moreover, once the legislator has chosen the instrument of the EU regulation, the aim was to create a standard system at the Community level in order to eliminate all barriers to free trade of the pharmaceutical product as well as the competitive distortions within the EU. Indeed, different expiration dates in different member states of the European Community would lead to an undesirable parallel trade within the Community between the states where the SPC has already expired and those with the valid protection. Apart from splitting the market, this situation would create a legal uncertainty for the market players.

Regarding the second question, the Greek, Lithuanian, and Latvian governments were of the opinion that the date of issuance of the MA is decisive. The Advocate-General and the CJEU however, came to the opposite conclusion. According to their determination, the wording of the Regulation does not answer this question directly, nor does the preceding case law clarify what date is precisely meant. However, considering that the purpose of supplementary protection is to extend patent protection eroded by the long-lasting authorization proceeding for pharmaceutical products, and thus to recoup costly investments into clinical trials, both legal texts and case law have always emphasized the importance of warranting an adequate protection, especially with respect to the term of such protection. A right to market a pharmaceutical product and to amortize the development costs arises first at the point where the right holder becomes aware of the decision to approve marketing of the product. It would be unacceptable if the envisaged extension of the protection is shortened by the procedure between the issuance and notification—which, moreover, cannot be influenced by the applicant.

It should also be emphasized that the European Commission systematically applies this interpretation in handling SPCs for medicinal products approved in the Community for other purposes. Also, the European Medicine Agency considers the date of notification when determining the protection period that must be considered for subsequent generic/hybrid applications.


This decision brings welcome news for SPC applicants. First, the duration of SPCs will be now calculated uniformly across the entire European Economic Area, improving legal certainty in the field of SPCs. Second, in those countries that have used the issuance date of the MA, the duration of SPC protection will be extended.

The open question is what effect this decision will have on previously granted SPCs. The practice of the national patent offices is not uniform. Some issue SPCs with the term and others without. Considering that the term is determined by the (directly applicable) SPC Regulation, as interpreted by the CJEU, it can be argued that any term indicated by a grant decision of a national office is only declaratory. Still, applicants may want to request updates of such decisions setting out the "wrong" term for the avoidance of any doubt.

It also remains unclear how the similar but not identical wording of Art. 7(1) of the SPC Regulation "the date on which the authorization ... is granted" should be interpreted. This article regulates the deadline for filing SPC applications. Although in Art. 7(1) the grant is explicitly indicated, it is still unclear whether the date on which the decision is granted or the date of its notification is meant.

The CJEU missed an opportunity to contribute to the clarification of this ambiguous formulation. Certainly, there will be attempts to argue the analogous application of this decision in future cases.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Christian Fulda
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions